Pfizer suspends a U.S. trial due to a lack of volunteers. It is not a technical problem; it is an early warning of a potential non-technical limit in biomedical innovation. By Ehab Soltan HoyLunes — In biomedical innovation, we usually assume that limits are technical or financial. Reality is beginning to contradict that idea. Imagine that we have built…
Read MoreThe Ghost Patient: Why the Most Advanced Biomedicine Risks Becoming Irrelevant
